FDA clears new 3D brain imaging technology, provides CTA support of stroke
The FDA has recently approved iSchemaView’s RAPID CTA, a new 3D imaging technology for computed tomography (CT) angiography, according to a May 1 release.
The technology is designed to provide faster, high quality images of blood vessels in brains of patients with cerebrovascular conditions such as stroke.
“Our goal is to provide healthcare professionals around the world with the most comprehensive and intuitive suite of imaging solutions possible,” said Don Listwin, CEO of iSchemaView, in a prepared statement. “We ensure physicians can take advantage of RAPID’s power whether they choose plain CT, CT angiography, CT perfusion or MR diffusion and perfusion; it’s all about offering them the right imaging solution choice, for the right patient at the right time.”
RAPID CTA provides 3D CTA maps with colored overlays to help identify regions in the brain with reduced blood vessel density. Physicians are then able to rotate the 3D image of the vessels in minutes, either while in a clinical setting or remotely from any desktop or mobile device, according to the release.
Ultimately, iSchemaView believes its technology will allow for more efficient clinical decision-making, patient triage and collaboration between community hospitals and specialists.
“The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer,” said Greg Albers, MD, professor of neurology at Stanford University and director of the Stanford Stroke Center and cofounder of iSchemaView, according to the press release. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are.”